

1 **Label-free imaging of immune cell dynamics in the living**
2 **retina using adaptive optics**

3 Aby Joseph^{1,*}, Colin J Chu^{2,*}, Guanping Feng³, Kosha Dholakia⁴, Jesse Schallek^{4,5,6}

- 4 1. *The Institute of Optics, University of Rochester, Rochester, NY, US*
5 2. *Translational Health Sciences, University of Bristol, Bristol, United Kingdom.*
6 3. *Department of Biomedical Engineering, University of Rochester, Rochester, NY, US*
7 4. *Flaum Eye Institute, University of Rochester, Rochester, NY, US*
8 5. *Department of Neuroscience, University of Rochester, Rochester, NY, US*
9 6. *Center for Visual Science, University of Rochester, Rochester, NY, US*

10

11 * These authors contributed equally. Co-first authors.

12 Correspondence: Colin Chu (colin.chu@bristol.ac.uk) or Aby Joseph
13 (ajoseph9@ur.rochester.edu) or Jesse Schallek (jschall3@ur.rochester.edu).

14

15 **Abstract**

16 Our recent work characterized the movement of single blood cells within the retinal
17 vasculature of healthy mice (Joseph et al. 2019) using adaptive optics ophthalmoscopy. Here
18 we apply this technique to the context of acute inflammation and discover both infiltrating and
19 tissue-resident immune cells to be visible without any labelling in the living retina using near-
20 infrared light alone. Intravital imaging of immune cells can be negatively impacted by surgical
21 manipulation, exogenous dyes, transgenic manipulation and phototoxicity. These confounds
22 are now overcome, using phase contrast and time-lapse videography to reveal the dynamic
23 behavior of myeloid cells as they interact, extravasate and survey the retina. Cellular motility
24 and differential vascular responses can be measured noninvasively and *in vivo* across hours
25 to months at the same retinal location, from initiation to the resolution of inflammation. As
26 comparable systems are already available for clinical research, this approach could be readily
27 translated to human application.

28 **Impact statement**

29 Immune cell motility and vascular response are imaged *in vivo* and label-free in the CNS for
30 the first time, using high-resolution phase-contrast adaptive optics retinal imaging.

31 **Introduction**

32 A robust and noninvasive method for directly imaging immune cells in humans has not been
33 established, limiting our understanding of autoimmune and inflammatory disease. Immune
34 cells typically provide weak optical contrast requiring exogenous or transgenic labelling for
35 detection even in animal models. The eye is optimally suited to image immune responses *in*
36 *vivo* [1]. As the only transparent organ in mammals, no inflammatory surgical or environmental
37 perturbation is required. However, aberrations of the otherwise clear optics of the eye limit

38 achievable image resolution. We employed a custom adaptive-optics-scanning-light-
39 ophthalmoscope (AOSLO) to image the mouse eye. By correcting for the eye's aberrations,
40 single-cell resolution provides detailed imaging of photoreceptors to erythrocytes [2–4].
41 Incorporating our recent report [5] on phase contrast approaches allowed deep tissue detection
42 of translucent cells [6,7]. We combined and applied these strategies and serendipitously
43 discovered that immune cells could be imaged without labelling using 796 nm near-infrared
44 light, to which the eye is insensitive, and at far lower levels (<500 μ W) than multiphoton
45 systems that can be phototoxic [8]. This new approach builds on our ability to quantify single-
46 cell blood flow in vessels [2] revealing the dynamic interplay of blood flow and single immune
47 cells in response to inflammation in the living eye.

48 **Results and Discussion**

49 To model an immune response, ocular injection of lipopolysaccharide (LPS) was used to
50 provide an acute but self-resolving inflammatory stimulus [9]. Potential immune cells were
51 observed adjacent to retinal veins only after meticulous image registration, frame averaging
52 and time-lapse imaging (**Fig. 1A, Video 1**). Membrane remodelling, pseudopodia formation
53 and motility consistent with immune cells was visible, distinct from static neurons or macroglia
54 (**Fig. 1B & Video 2**). Within post-capillary venules, leukocyte rolling, crawling, and trans-
55 endothelial migration behaviours were detectable (**Fig. 1C, Videos 3 and 4**). Heterogeneity
56 in cell distribution, size and morphology was imaged with multiple cell types in different stages
57 of interaction (**Fig. 1D**).

58
59 We verified these cells comprised neutrophil and monocyte populations by fluorescent marker
60 co-localization. Simultaneous phase contrast and confocal fluorescence AOSLO revealed
61 most leukocytes rolling along venular endothelium were neutrophils using intravenous anti-

62 Ly6G antibody labelling (**Fig. 1E, Video 5**). Conversely, $CD68^{GFP/+}$ mice distinguished a
63 population of cells were infiltrating monocytes and macrophages present both in vessels and
64 extravasated into retinal tissue (**Fig. 1F**). More cells were visible using phase contrast than
65 by fluorescence labelling, demonstrating its utility for comprehensively detecting diverse and
66 mixed cellular populations. Tissue resident myeloid cells were also visible by AOSLO phase
67 contrast even in healthy eyes without LPS injection. These were confirmed as microglia or
68 hyalocytes by colocalization of $Cx3cr1^{GFP/+}$ and $CD68^{GFP/+}$ fluorescence (**Fig. 1G-I**) [10]. Phase
69 contrast even revealed subcellular features, including structures that could represent internal
70 processes such as endosomes (**Fig. 1H, Video 6**) [11].

71
72 As our approach is uniquely non-invasive, repeated imaging at the same tissue location
73 permits longitudinal study throughout the initiation, peak and resolution of an immune
74 response across hours to months within individual eyes (**Fig. 1J, Video 7**). To quantify
75 immune cell behaviour in these studies, we had to distinguish immune cells from surrounding
76 tissue by developing semi-automated deep learning software [12]. This correlated well with
77 counts made by masked human observers ($R^2=0.99$, $P=0.004$, **Video 8 (last part)**).

78
79 Immune cell metrics were quantified in six mice over five timepoints following LPS injection
80 (**Fig. 2A-C**). Compared to baseline (28.9 ± 34.1 cells/mm², Mean \pm SD) a 7-fold influx of cells
81 was detected by six hours post injection (208.3 ± 108.6 cells/mm²) rising to over an 18-fold
82 increase by 24 hours (510.4 ± 441 cells/mm²) before returning towards baseline at 72-hours
83 (59.0 ± 27.8 cells/mm²) and 10-days (69.4 ± 41.7 cells/mm²). AOSLO also allowed cell motility
84 quantification with maximum cell displacement observed at 6 hours (16.1 ± 9.9 μ m, n=12
85 cells). Despite peak infiltration at 24-hours, motility was greatly reduced (4.6 ± 4.3 μ m, n = 58
86 cells), best appreciable by longitudinal imaging, consistent with Resolvin-mediated
87 suppression of chemotaxis [13].


88

89 As retinal tissue is not depressurized by this intravital system, true vascular alterations arising
90 from inflammation can be isolated and correlated to simultaneous immune cell measurements.
91 Adapting our recent work [2], red blood cell (RBC) velocimetry, vessel dilation and flow-rate
92 changes were quantified in this same cohort of mice (**Fig. 2D-H**). AOSLO revealed micron-
93 level vascular dilations and heterogeneous changes in blood flow in arterioles and venules in
94 response to LPS. Total blood flow increased in the retinal circulation, yet elevated flow in
95 arterioles and venules was achieved in fundamentally different ways. Venules dilated on
96 average 36% ($\pm 8\%$) at 24-hours post LPS injection facilitating a total flow increase of 67%
97 ($\pm 27\%$) relative to baseline. Conversely, arterioles showed minimal dilation yet dramatically
98 elevated RBC velocity (48% increase ($\pm 31\%$) at 24-hours (**Fig. 2D-F**). Despite these different
99 mechanisms, conservation of flow was confirmed as arterioles and venules showed correlated
100 changes in flow over time ($R^2=0.83$, for linear-fit, **Fig. 2G-H**). Velocity, dilation and flow began
101 resolution towards baseline levels by 10-days post-injection. The balanced asymmetry
102 between arterioles and venules is a new finding in our understanding of hemodynamic control
103 in response to inflammation, achieved by applying our recently developed tool [2].


104
105 This study advances our understanding of the immune response by imaging both the nuanced
106 differences of the vascular perfusion with the first detailed imaging of single immune cell
107 activity imaged without labels. Unlike other approaches, inflammatory surgery is not required,
108 the label-free feature avoids confounding by exogenous fluorescent dyes, gene haplo-
109 insufficiency from transgenic labels and using near-infrared light avoids phototoxicity inherent
110 to multiphoton platforms [8,14]. By providing this proof of concept, as AOSLO systems are
111 already available for clinical research the approach stands to be rapidly translated to human
112 application.

113


Infiltrating immune cells



Resident immune cells




Longitudinal timecourse



114
115
116
117
118
119
120
121
122
123
124
125
126

Figure 1. Label-free adaptive optics imaging of infiltrating and tissue resident immune cells in the retina. **A**, widefield image showing venule baseline and 72-hours after LPS injection. AOSLO montage (*red rectangle*) detects dispersed immune cells. **B**, detail of heterogeneous immune cells **C**, Intravascular trans-endothelial migration (TEM) stages are visible. **D**, field adjacent to vein 72-hours after LPS. **E**, simultaneous phase-contrast and anti-Ly6G fluorescence reveals leukocyte rolling (*arrowheads*) and **F**, CD68-GFP reporter shows extravascular and intravascular cells. **G**, Representative examples of tissue-resident myeloid cells from *Cx3cr1*-GFP and **H**, CD68-GFP reporter mice showing colocalization of fluorescence with label-free cells. **I**, phase-contrast image of process remodelling. **J**, longitudinal imaging (hours-to-months) at same location following LPS injection. Scale bars =10 μ m, except in **A** =50 μ m.



127
 128 **Figure 2. Longitudinal non-invasive measurement of combined immune cell dynamics and**
 129 **vascular flow.** Measurements of neighbouring venules, arterioles and connecting parenchyma. **A**,
 130 AOSLO phase-contrast images of same region across five timepoints relative to LPS injection. Scale
 131 bar =30 μm . **B**, Magnified image of one cell (marked overlay) with tracked trace (100 seconds). **C**,
 132 Cell displacements for total cohort at indicated timepoints. Displacement traces normalized to each cell
 133 starting position. Grey dashes indicate radius of typical cell size (13 μm). **D**, Space-time images with
 134 overlaid single-cell blood velocity. Arteriolar velocity increases then resolves. Scale bars=200 ms
 135 horizontal, 30 μm vertical. **E**, Vessel diameter visualized in motion-contrast images of venules (blue)
 136 and arterioles (red). Venule diameter dilates then resolves. Scale bar=30 μm **F**, Population values of
 137 RBC velocity change relative to baseline, lumen diameter and flow rate for venules and arterioles. Vein
 138 diameter ($p=0.008$) and artery velocity ($p=0.036$) exhibit significant changes across time (Friedman
 139 test, $n=6$ mice). Mean+SD shown. **G**, Correlation of change in flow between arterioles and venules,
 140 (colors correspond to timepoints in **A**). **H**, Change in ratio V/D^2 , plotted across timepoints from **F**
 141 (V =velocity, D =diameter). Flow-rate is proportional to the product $V \cdot D^2$.

METHODS

142
143
144

Mouse strains

145 All mice were sourced from The Jackson Laboratory (Bar Harbor, Maine, USA) and maintained
146 at the University of Rochester in compliance with all guidelines from the University Committee
147 on Animal Resources and according to the Association for Research in Vision and
148 Ophthalmology statement for the Use of Animals in Ophthalmic and Vision Research. Mice were
149 fed with standard laboratory chow *ad libitum* and housed under a 12-hour light-dark cycle. 6 to
150 12-week old male mice were employed from three strains: C57BL/6J (Stock number 000664),
151 *hCD68-GFP* (Stock number 026827) and *Cx3cr1-GFP* hemizygotes (Stock number 005582).

152

Mouse preparation for imaging

154 Mice underwent anesthetic induction with intraperitoneal Ketamine (100 mg/kg) and Xylazine (10
155 mg/kg) before maintenance on 1% v/v isoflurane and supplemental oxygen through a nose
156 cone. Pupils were dilated with a single drop of 1% Tropicamide and 2.5% phenylephrine (Akorn,
157 Lake Forest, IL, USA). Internal temperature was controlled using an external heating pad
158 adjusted to maintain continuous 37.0 degrees Celsius with monitoring via a rectal probe electrical
159 thermometer (Physiosuite, Kent). A rigid contact lens of 1.6mm base curve and +10 Dioptre
160 correction was placed centrally on the cornea and lubrication of the eye maintained by aqueous
161 lubricant (GenTeal, Alcon Laboratories, Fort Worth, TX, USA) during imaging. The eye was
162 imaged in free space meaning there was no physical contact with the AOSLO, ensuring no
163 compression causing alteration of intraocular pressure.

164

Endotoxin induced uveitis model

166 Following anesthesia, intravitreal injection with a 34-gauge Hamilton microsyringe through the
167 pars plana was used to deliver 0.5 ng of lipopolysaccharide (LPS) from *E.coli* 055:B5 (Sigma) in
168 a one microlitre volume of phosphate buffered saline (PBS) [9]. Only one eye of each mouse
169 was injected and used for the study.

170 **Intravenous antibody labelling**

171 2 µg of primary conjugated anti-mouse Ly6G-Alexa Fluor 647 (clone 1A8, Biolegend) diluted into
172 200 µl PBS were injected intravenously via tail vein ten minutes prior to imaging as previously
173 published [15,16].

174

175 **AOSLO imaging**

176 Mice were imaged with a custom adaptive optics scanning light ophthalmoscope (AOSLO), using
177 near-infrared light (796±17 nm, 200-500 µW, super luminescent diode: S790-G-I-15, Superlum,
178 Ireland) [2,17]. Phase-contrast imaging referred to in the context of this paper, was achieved by
179 purposefully displacing the detector axially to a plane conjugate to the highly reflective
180 RPE/choroid complex, to enable detection of forward and multiply scattered light from translucent
181 cells, as detailed in our recent publication [5]. In a subset of experiments for confirmation of
182 immune cell types, fluorescence was simultaneously imaged using 488 nm excitation and
183 520±35 emission for GFP, and 640 nm excitation and 676±29 emission for Alexa Fluor 647
184 (excitation laser diode: iChrome MLE, Toptica Photonics, Farmington, New York, USA; emission
185 filters: FF01-520/35-25 and FF01-676/29-25, Semrock, Rochester, New York, USA). Mice also
186 underwent imaging with HRA+OCT Spectralis (Heidelberg Engineering, Germany).

187

188 **Aberration measurement and correction with adaptive optics**

189 Aberrations in the mouse eye were measured and corrected with a closed-loop adaptive optics
190 system operating at 13 corrections per second, built at the University of Rochester and described
191 previously [2,17]. Aberrations were measured with a Hartmann-Shack wavefront sensor using a
192 904 nm wavefront beacon (QFLD-905–10S, QPhotonics, Ann Arbor, Michigan, USA) imaged
193 onto the retina. Aberration correction was achieved with a continuous membrane deformable
194 mirror with 97 actuators (DM-97-15, ALPAO, France).

195

196 **Imaging videography**

197 The AOSLO is a raster-scanning instrument with a resonant scanner frequency of 15 kHz and
198 25 Hz orthogonal scanning rendering the retina at 25 frames per second. Point scanning readout
199 was achieved by two photomultiplier tubes (PMTs) for visible and near infrared wavelengths
200 (H7422–40 and H7422–50, Hamamatsu, Japan). Frame size was 608 by 480 pixels and the
201 image distortion introduced by sinusoidal scanning was corrected in real-time [18]. Field sizes
202 were between 2-5 degrees of visual angle corresponding to 68-170 microns in retinal space.
203 Typical imaging sessions lasted ~2 hours and semi-continuous video acquisition of a target
204 retinal location was conducted for up to 30 minutes. AOSLO retinal data was visualized in real-
205 time to facilitate user tracking, correction and optimization and saved for subsequent post-
206 processing.

207

208 **Image registration and time-lapse analysis**

209 To correct for residual motion of the eye, image registration was performed with custom
210 software [18,19]. Time-lapse videos were generated using running frame-averaging of 25-50
211 frames (from 25 Hz native frame rate of AOSLO) with ImageJ and Fiji (National Institutes of
212 Health, USA) [20]. Montaging multiple fields in Fig. 1a was performed by stitching and blending
213 overlapping 4.98 degree fields manually using Adobe Photoshop (Version: CS6 Extended
214 v13.0.1 x64).

215

216 **Statistical analysis**

217 Pearson correlation and Freidman tests were performed using Prism 7.0 (GraphPad Software)
218 and linear curve-fitting in MATLAB 2020a, version 9.8.0.

219

220 **Cell migration measurement**

221 Retinal locations were imaged for 100 seconds for six mice at five timepoints (baseline, 6, 24,
222 72-hours and 10-days post LPS injection). Sixty AOSLO phase-contrast videos were used to
223 analyse the migration of extravasated cells. Registered videos were pre-processed by cropping

224 to 512x400 pixels and temporally averaged with five frames. A customized semi-automated
225 deep-learning based cell tracking software was employed to track and quantify the migration
226 behaviour of cells. The software consisted of a deep learning-based cell detector with an
227 encoder-decoder U-Net backbone architecture [12,21]. The U-Net was trained on phase-contrast
228 AOSLO images with the centroids of 387 cells manually identified by expert graders obtained
229 from four mice at either 6 or 24-hours post LPS injection. Immune cell data from mice imaged for
230 training were excluded from the final analysis of the results in this paper. The trained U-Net
231 outputs a probability map for each frame of a video that was thresholded ($\geq 90\%$) to identify the
232 centroids of cells. The cell counts of a video were calculated by averaging the number of detected
233 objects in the first 25 frames (5 seconds). To track the cells, centroid positions detected by the
234 U-Net in adjacent frames were linked with a nearest neighbor search algorithm [21]. The deep
235 learning strategy facilitated tracking of a large number of cells across multiple frames captured
236 at different time points across inflammation. Once the heavy burden of tracking this population
237 over a large data set was complete, a human user provided quality control of the automated
238 outputted traces to confirm tracking fidelity. Traces due to incorrect linkage (for example, a single
239 trace that falsely jumped between two adjacent cells) were manually rejected based on visual
240 inspection (Fig. 2b, Video 8). To quantify cell migration, two quantities were extracted from the
241 traces: 1. cell displacement which is defined as the displacement of a cell over 100 seconds. 2.
242 confinement ratio which is defined as the ratio of cell displacement and the total path length over
243 100 seconds. Traces in Fig. 2c indicate the total positional movement and direction of movement
244 relative to cell position in the first second of data collection. The U-Net based cell detection was
245 performed with Python 3.7 and PyTorch 1.0.1, while the tracking and quantification procedures
246 were based on MATLAB.

247

248 **Blood flow measurement**

249 Single cell blood flow was imaged and measured with near infrared light using our recently
250 published approach [2], for the same six mice and five timepoints as above, in an arteriole and

251 venule surrounding the tissue location at which the cell migration measurements above were
252 done. Briefly, a fast 15 kHz beam (796 Δ 17 nm) was scanned across a vessel of interest to image
253 passing blood cells without requiring contrast agent. Cellular-scale blood velocity and vessel
254 diameter were quantified automatically. Given the small size of even the largest mouse retinal
255 vessels (<45 μ m inner diameter in healthy mice), the spatial resolution of our approach
256 accurately measured the inner lumen diameter with micrometer precision, accounting for vessel
257 tortuosity, vascular wall thickness and cell-free plasma layer. Additionally, the temporal
258 resolution of the velocity detection approach was more than sufficient to measure and account
259 for cardiac pulsatility in flow, as demonstrated previously. This ensured accurate measurement
260 of the average blood velocity through the vessel. Combined, the volumetric flow rate through the
261 vessel was quantified label-free. The non-invasive approach enabled us to track blood flow
262 longitudinally from hours to weeks over the course of inflammation without requiring invasive
263 injections or euthanasia after a single timepoint was imaged.

264

265 **Code availability statement**

266 Single-cell blood flow was measured using our recently published approach [2], with custom
267 code written in MATLAB R2017a (Version 9.2, with Image Processing Toolbox, MathWorks,
268 Massachusetts, USA). Source code is available in public repository here:
269 https://github.com/abyjoseph1991/single_cell_blood_flow. Other code used in the study is
270 available from corresponding authors upon reasonable request.

271

272 **Acknowledgments**

273 The authors wish to thank Qiang Yang, Andres Guevara, Rachel Hollar, Jennifer Strazzeri and
274 Karteek Kunala for their technical contributions to this work. We are grateful to Andrew Dick and
275 Richard Lee for their guidance and helping establish this collaboration. We thank David Williams
276 and Robin Sharma for their critical feedback on the manuscript.

277

278 **Funding**

279 Research was supported by the National Eye Institute of the National Institutes of Health under
280 R01 EY028293, and P30 EY001319. The content is solely the responsibility of the authors and
281 does not necessarily represent the official views of the National Institutes of Health. Research
282 was also supported by an unrestricted grant to the University of Rochester Department of
283 Ophthalmology, a Career Development Award and Stein Award from Research to Prevent
284 Blindness (RPB), New York; a research grant from Hoffman-LaRoche (Roche pRED) and the
285 Dana Foundation David Mahoney Neuroimaging Award (Schallek). CJC received support from
286 a WUN Research Mobility Programme award, National Institute for Health Research (NIHR) and
287 National Eye Research Centre, UK.

288

289 **Disclosures**

290 Joseph, Feng, Dholakia, Schallek: Received funding support from Hoffman-La Roche Inc.
291 Roche participated in conceptualization of certain aspects of the project, but did not participate
292 in data collection, data analysis, decision to publish or preparation of the manuscript. Joseph and
293 Schallek: Hold patents and/or patent applications on adaptive optics technology filed through the
294 University of Rochester.

295

296

297 **References**

298

- 299 1. J. T. Rosenbaum, S. R. PLANCK, T. M. MARTIN, I. CRANE, H. XU, and J. V.
300 FORRESTER, "Imaging Ocular Immune Responses by Intravital Microscopy," *Int. Rev.*
301 *Immunol.* **21**, 255–273 (2002).
- 302 2. A. Joseph, A. Guevara-Torres, and J. Schallek, "Imaging single-cell blood flow in the
303 smallest to largest vessels in the living retina," *eLife* **8**, e45077 (2019).
- 304 3. J. Liang, D. R. Williams, and D. T. Miller, "Supernormal vision and high-resolution retinal
305 imaging through adaptive optics," *J. Opt. Soc. Am. A* **14**, 2884 (1997).

- 306 4. A. Roorda and J. L. Duncan, "Adaptive Optics Ophthalmoscopy," *Annu. Rev. Vis. Sci.* **1**,
307 19–50 (2015).
- 308 5. A. Guevara-Torres, D. R. Williams, and J. B. Schallek, "Origin of cell contrast in offset
309 aperture adaptive optics ophthalmoscopy," *Opt. Lett.* **45**, 840–843 (2020).
- 310 6. T. Y. P. Chui, D. A. VanNasdale, and S. A. Burns, "The use of forward scatter to improve
311 retinal vascular imaging with an adaptive optics scanning laser ophthalmoscope," *Biomed.*
312 *Opt. Express* **3**, 2537 (2012).
- 313 7. D. Scoles, Y. N. Sulai, C. S. Langlo, G. A. Fishman, C. A. Curcio, J. Carroll, and A. Dubra,
314 "In Vivo Imaging of Human Cone Photoreceptor Inner Segments," *Invest. Ophthalmol. Vis.*
315 *Sci.* **55**, 4244–4251 (2014).
- 316 8. R. Galli, O. Uckermann, E. F. Andresen, K. D. Geiger, E. Koch, G. Schackert, G. Steiner,
317 and M. Kirsch, "Intrinsic Indicator of Photodamage during Label-Free Multiphoton
318 Microscopy of Cells and Tissues," *PLOS ONE* **9**, e110295 (2014).
- 319 9. C. J. Chu, P. J. Gardner, D. A. Copland, S. E. Liyanage, A. Gonzalez-Cordero, S.-M. kleine
320 Holthaus, U. F. O. Luhmann, A. J. Smith, R. R. Ali, and A. D. Dick, "Multimodal analysis of
321 ocular inflammation using the endotoxin-induced uveitis mouse model," *Dis. Model. Mech.*
322 **9**, 473–481 (2016).
- 323 10. H. S. Lazarus and G. S. Hageman, "In Situ Characterization of the Human Hyalocyte,"
324 *Arch. Ophthalmol.* **112**, 1356–1362 (1994).
- 325 11. S. Uderhardt, A. J. Martins, J. S. Tsang, T. Lämmermann, and R. N. Germain, "Resident
326 Macrophages Cloak Tissue Microlesions to Prevent Neutrophil-Driven Inflammatory
327 Damage," *Cell* **177**, 541-555.e17 (2019).
- 328 12. T. Falk, D. Mai, R. Bensch, Ö. Çiçek, A. Abdulkadir, Y. Marrakchi, A. Böhm, J. Deubner,
329 Z. Jäckel, K. Seiwald, A. Dovzhenko, O. Tietz, C. Dal Bosco, S. Walsh, D. Saltukoglu, T. L.
330 Tay, M. Prinz, K. Palme, M. Simons, I. Diester, T. Brox, and O. Ronneberger, "U-Net: deep
331 learning for cell counting, detection, and morphometry," *Nat. Methods* **16**, 67–70 (2019).

- 332 13. J. M. Schwab, N. Chiang, M. Arita, and C. N. Serhan, "Resolvin E1 and protectin D1
333 activate inflammation-resolution programmes," *Nature* **447**, 869–874 (2007).
- 334 14. S. You, H. Tu, E. J. Chaney, Y. Sun, Y. Zhao, A. J. Bower, Y.-Z. Liu, M. Marjanovic, S.
335 Sinha, Y. Pu, and S. A. Boppart, "Intravital imaging by simultaneous label-free
336 autofluorescence-multiharmonic microscopy," *Nat. Commun.* **9**, 2125 (2018).
- 337 15. A. Marki, K. Buscher, Z. Mikulski, A. Pries, and K. Ley, "Rolling neutrophils form tethers
338 and slings under physiologic conditions in vivo," *J. Leukoc. Biol.* **103**, 67–70 (2018).
- 339 16. A. Woodfin, M.-B. Voisin, M. Beyrau, B. Colom, D. Caille, F.-M. Diapouli, G. B. Nash, T.
340 Chavakis, S. M. Albelda, G. E. Rainger, P. Meda, B. A. Imhof, and S. Nourshargh, "The
341 junctional adhesion molecule JAM-C regulates polarized transendothelial migration of
342 neutrophils *in vivo*," *Nat. Immunol.* **12**, 761–769 (2011).
- 343 17. Y. Geng, A. Dubra, L. Yin, W. H. Merigan, R. Sharma, R. T. Libby, and D. R. Williams,
344 "Adaptive optics retinal imaging in the living mouse eye," *Biomed. Opt. Express* **3**, 715–734
345 (2012).
- 346 18. Q. Yang, L. Yin, K. Nozato, J. Zhang, K. Saito, W. H. Merigan, D. R. Williams, and E. A.
347 Rossi, "Calibration-free sinusoidal rectification and uniform retinal irradiance in scanning
348 light ophthalmoscopy," *Opt. Lett.* **40**, 85–88 (2015).
- 349 19. A. Dubra and Z. Harvey, "Registration of 2D Images from Fast Scanning Ophthalmic
350 Instruments," in *Biomedical Image Registration*, Lecture Notes in Computer Science
351 (Springer, Berlin, Heidelberg, 2010), pp. 60–71.
- 352 20. J. Schindelin, I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, S.
353 Preibisch, C. Rueden, S. Saalfeld, B. Schmid, J.-Y. Tinevez, D. J. White, V. Hartenstein, K.
354 Eliceiri, P. Tomancak, and A. Cardona, "Fiji: an open-source platform for biological-image
355 analysis," *Nat. Methods* **9**, 676–682 (2012).
- 356 21. H.-F. Tsai, J. Gajda, T. F. W. Sloan, A. Rares, and A. Q. Shen, "Usiigaci: Instance-aware
357 cell tracking in stain-free phase contrast microscopy enabled by machine learning,"
358 *SoftwareX* **9**, 230–237 (2019).

359 **Supporting information: video legends**

360 **Video 1 (separate file).** Demonstration of image post-processing. a. Raw adaptive optics
361 scanning light ophthalmoscope (AOSLO) corrected 796nm phase contrast imaging of C57BL/6J
362 mouse retina. Real-time video obtained at 25 fps acquisition (labelled “raw acquisition”)
363 demonstrating movement from respiration and cardiac output. Image following custom frame-
364 registration. Application of 25 frame temporal averaging and accelerated time-lapse (labelled
365 “frame averaging”). Top row, cluster of infiltrated immune cells 6 hours post-LPS. Bottom row,
366 tissue resident cell in healthy retina adjacent to a retinal capillary. Scale bars = 10 μ m.

367 **Video 2 (separate file).** Label-free AOSLO time-lapse video demonstrating heterogenous
368 immune cell populations and motility. Two magnified locations from Fig. 1b showing 796nm
369 phase contrast video acquired at 25 frames per second from two C57BL/6J mouse retinas 24
370 hours post-LPS injection. The second segment of the video is a full 4.98-degree AOSLO field at
371 a retinal vein 48-hours after LPS injection, revealing a diversity of cell morphologies and motility
372 patterns. Videos have undergone post-processing as described, 25-50 frame temporal
373 averaging. Scale bars = 10 μ m.

374 **Video 3 (separate file).** Leukocyte rolling and crawling in an inflamed retinal post-capillary
375 venule. 796nm phase contrast AOSLO images taken at 6 hours post-LPS injection with 25 frame
376 temporal averaging. Descriptive overlays provided. Scale bar = 10 μ m.

377 **Video 4 (separate file).** Examples of diverse immune cell behaviour observable by AOSLO
378 phase contrast imaging. 796nm reflectance AOSLO images at 6 or 24 hours post-LPS using
379 between 5 to 50 frame averaging. Examples include post-capillary venule leukocyte rolling,
380 transendothelial migration and perivascular leukocyte accumulation, venous leukocyte rolling
381 and crawling with and against blood flow direction, mid tissue infiltrating leukocyte swarming,
382 perivascular cell process contact with intravascular cell and cell migration towards lumen of
383 retinal vein. Scale bars = 10 μ m.

384 **Video 5 (separate file).** Neutrophil endothelial rolling within a post-capillary venule confirmed
385 using fluorescent labelling with anti-Ly6G antibody. Representative example of retinal vein
386 imaged six hours post LPS injection. Simultaneous aligned acquisition of 796nm phase contrast
387 (top panel) and anti-Ly6G conjugated AlexaFluor 647 (positively labelling neutrophils in bottom
388 panel) using confocal AOSLO fluorescence. Scale bar = 10 μm .

389 **Video 6 (separate file).** Cx3cr1-GFP+ tissue resident cell with motile processes. Simultaneous
390 aligned acquisition of 796nm phase contrast (left panel) and GFP fluorescence (right panel) in
391 healthy retina from Cx3cr1GFP/+ reporter mouse. Second section demonstrates process
392 retraction in tissue resident myeloid cell. Third section illustrates diversity of morphology
393 observed. Forth section highlights visible sub-cellular features in this population. Scale bar = 10
394 μm .

395 **Video 7 (separate file).** Repeated longitudinal imaging of the same retinal location from initial
396 inflammation to resolution. Representative recordings from one C57BL/6J mouse at the same
397 anatomical location in the retina, identifiable by peripapillary location and capillary and vascular
398 landmarks. Recorded prior to and 6, 24, 72 hours, 10 days and 2 months following a single LPS
399 injection. Scale bar = 10 μm .

400 **Video 8 (separate file).** U-Net cell tracking trace example. Recording from C57BL/6J mouse
401 retina at 6 hours post LPS injection. Whole field imaged and quantified is shown on the left side.
402 Magnification of one representative cell on the right. Scale bar = 16 μm . Trace is marked with an
403 overlaid magenta line. Second section shows validation of U-Net cell